GlassScriptPhysician profile
Helen Skolnick
NPI 1962409755
$6,441.53
in general payments reported to CMS, 2019-2025
24 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $1,075 · 2021: $893 · 2022: $943 · 2023: $666 · 2024: $804 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.18 |
| Education | $117.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,759.37 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Optinose US, INC. | $899.63 | 2019-2024 | |
| Glaxosmithkline, LLC. | $811.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $389.36 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $325.02 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $303.35 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $258.45 | 2019-2025 | |
| Csl Behring | $247.04 | 2022-2025 | Haegarda, Andembry |
| Genzyme Corporation | $218.39 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $201.60 | 2021 | |
| Kaleo, INC. | $199.64 | 2019-2024 | Auvi-Q |
| Amgen INC. | $131.31 | 2021-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $117.98 | 2023-2025 | |
| Pharming Healthcare, INC. | $117.00 | 2022-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $104.23 | 2020-2025 | Eohilia, Takhzyro |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.34 | 2020-2021 | |
| Organon LLC | $71.85 | 2025 | |
| Aimmune Therapeutics, INC. | $47.68 | 2022 | |
| Incyte Corporation | $35.79 | 2022 | |
| Biocryst US Sales Co., LLC | $35.11 | 2025 | Orladeyo |
| Hikma Pharmaceuticals USA | $31.98 | 2024 | Ryaltris |
| Phadia US INC. | $26.54 | 2024 | Immunocap |
| Ionis Pharmaceuticals, INC. | $17.61 | 2025 | Dawnzera |
| Pfizer INC. | $17.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Skolnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.